Sinus Tachycardia

• Sympathetic nervous system activation: Increased catecholamine release (epinephrine, norepinephrine) acts on β₁-adrenergic receptors in SA nodal tissue, accelerating the rate of diastolic depolarization and shortening the time to threshold. This increases the slope of phase 4 depolarization and lowers the maximum diastolic potential, resulting in more frequent action potentials.

• Parasympathetic withdrawal: Decreased vagal tone (reduced acetylcholine release) removes inhibitory effects on SA node automaticity. Acetylcholine normally increases potassium conductance and hyperpolarizes the membrane; its withdrawal allows faster spontaneous depolarization.

• Intrinsic SA node modulation: Increased intracellular calcium cycling, enhanced L-type calcium channel activity, and upregulation of hyperpolarization-activated cyclic nucleotide-gated (HCN) channels accelerate diastolic depolarization. Metabolic factors (elevated temperature, circulating metabolites) directly increase intrinsic pacemaker firing rate through temperature coefficient effects on ion channel kinetics.

• Hormonal influences: Thyroid hormones increase myocardial sensitivity to catecholamines and enhance β-adrenergic receptor expression. Elevated cortisol and other stress hormones potentiate sympathetic effects.

• Systemic compensatory mechanisms: In states of decreased cardiac output (heart failure, hypovolemia), baroreceptor reflex activation increases sympathetic outflow to maintain blood pressure and organ perfusion through increased heart rate (chronotropic effect).

Cardiovascular causes

• Acute coronary syndrome (ACS): Tachycardia serves as a compensatory mechanism; ST-elevation MI or unstable angina frequently present with sinus tachycardia
• Congestive heart failure: Reflects inadequate cardiac output and activation of compensatory mechanisms
• Cardiac arrhythmias: Supraventricular tachycardia (SVT), atrial fibrillation with rapid ventricular response (distinguish from sinus tachycardia by ECG characteristics)
• Myocarditis/pericarditis: Inflammatory cardiac disease triggers reflex tachycardia
• Hypertension: Both primary driver and consequence of sympathetic activation
• Valvular disease: Hemodynamic compromise necessitates increased heart rate
• Pulmonary embolism: Major cause requiring urgent recognition; tachycardia often prominent finding

Systemic/metabolic causes

• Fever/infection: Direct metabolic effect (approximately 10 bpm increase per 1°C); sepsis represents most dangerous presentation
• Thyrotoxicosis/hyperthyroidism: Increased myocardial β-adrenergic sensitivity; marked tachycardia often at rest
• Anemia: Compensatory mechanism to maintain oxygen delivery despite reduced hemoglobin
• Dehydration/hypovolemia: Baroreceptor-mediated sympathetic activation
• Pregnancy: Expanded blood volume and physiologic demands increase baseline heart rate by 10-20 bpm
• Malignancy: Tumor burden, cachexia, and paraneoplastic syndromes

Pulmonary causes

• Hypoxemia: Chemoreceptor activation increases sympathetic outflow
• COPD exacerbation: Hypoxia and CO₂ retention
• Asthma: Acute bronchospasm with respiratory compromise
• Pneumonia: Hypoxia and inflammatory mediators

Endocrine/metabolic

• Hypoglycemia: Sympathetic surge from adrenergic counterregulation
• Acidosis/alkalosis: Direct effects on SA node and reflex sympathetic activation
• Pheochromocytoma: Catecholamine excess

Iatrogenic/drug-related

• Sympathomimetics: Epinephrine, dopamine, dobutamine, albuterol, pseudoephedrine
• Anticholinergics: Atropine, antihistamines
• Stimulants: Caffeine, theophylline, cocaine, amphetamines
• Withdrawal states: Alcohol, benzodiazepines, beta-blockers
• Medications: Tricyclic antidepressants, corticosteroids

Psychological/behavioral

• Anxiety/panic disorder: Acute sympathetic activation
• Exercise/exertion: Physiologic response to increased metabolic demand
• Stress/pain: Sympathetic excitation
• Delirium: Often accompanied by tachycardia

Other causes

• Hyperthermia/heat exposure: Temperature-dependent increase in metabolic rate
• Postoperative state: Pain, stress, anesthesia recovery
• Chronic kidney disease: Anemia, hypertension, electrolyte abnormalities

Cardinal symptoms

• Palpitations: Awareness of forceful or rapid heartbeat, often more pronounced when lying down or at rest; may be accompanied by chest discomfort
• Dyspnea: Sensation of breathlessness; indicates either pulmonary pathology or inadequate cardiac output
• Chest pain/pressure: Particularly concerning for ACS; may represent angina or infarction necessitating urgent evaluation
• Syncope or presyncope: Suggests severely compromised cardiac output or underlying arrhythmia (though syncope from pure sinus tachycardia is uncommon and should raise suspicion for alternative diagnosis)
• Fatigue/malaise: General systemic symptoms reflecting underlying metabolic derangement or illness
• Diaphoresis: Cold, clammy skin suggesting sympathetic hyperactivity; highly concerning in context of chest pain

Physical examination findings

• Elevated heart rate: >100 bpm at rest by definition; character may be regular and forceful (brisk carotid upstroke) or bounding pulse depending on stroke volume
• Tachypnea: Often accompanies tachycardia, particularly in pulmonary or metabolic causes
• Fever: Classic sign of infection-related tachycardia; absence does not exclude sepsis
• Elevated blood pressure: Indicates sympathetic hyperactivity; may reflect both cause and consequence
• Cool, clammy extremities: Sign of poor perfusion; suggests cardiogenic shock or severe systemic illness
• Crackles on lung auscultation: Indicates pulmonary edema (heart failure) or pneumonia
• Gallop rhythm (S₃): Suggests ventricular dysfunction and heart failure
• Murmurs: New murmur may indicate acute valvular insufficiency (endocarditis, papillary muscle rupture)
• Hyperreflexia, tremor, warm skin: Suggest thyrotoxicosis
• Altered mental status: Delirium, agitation indicating systemic illness or hypoxia

Absence of findings

• Lack of orthostatic hypotension or clinical signs of hypovolemia may help exclude dehydration as primary cause
• Absence of fever does not exclude serious infection

12-lead electrocardiogram (ECG)

• Rate: 101-160 bpm (normal sinus tachycardia rarely exceeds 160 bpm at rest; faster rates suggest alternative arrhythmia)
• Rhythm: Regular, with constant PR interval and QRS duration
• P wave morphology: Upright P waves in leads I, II, aVF, and V2-V6 with normal configuration; P waves precede each QRS complex with fixed PR interval (0.12-0.20 seconds)
• PR interval: Normal (0.12-0.20 s); will shorten slightly with increasing heart rate
• QRS complex: Normal duration (<0.12 s); unchanged from baseline
• ST segments and T waves: May show nonspecific changes; presence of ST-elevation or depression requires investigation for ischemia
• Differentiation from SVT: Sinus tachycardia has gradual onset/offset, SVT has sudden onset; vagal maneuvers (carotid massage, Valsalva) may slow sinus tachycardia transiently but will not terminate it, whereas they may terminate SVT

Laboratory investigations

• Complete blood count: Assess for anemia (hemoglobin <7-8 g/dL typically causes compensatory tachycardia)
• Blood cultures: If fever or sepsis suspected; obtain before antibiotics
• Serum electrolytes: Hypokalemia, hypomagnesemia, hypocalcemia may lower threshold for arrhythmias; assess renal function
• Thyroid-stimulating hormone (TSH) and free T4: Essential screening if tachycardia unexplained; suppressed TSH with elevated free T4 indicates thyrotoxicosis
• Troponin (high-sensitivity if available): Essential in acute presentation with chest pain; serial measurements improve sensitivity for ACS
• Lactate: Elevated levels suggest tissue hypoperfusion or sepsis
• Arterial/venous blood gas: Assess oxygenation (hypoxemia), ventilation (CO₂), and pH (acidosis)
• Glucose: Hypoglycemia or hyperglycemia with diabetic ketoacidosis
• Inflammatory markers: C-reactive protein (CRP), erythrocyte sedimentation rate (ESR) for infection/inflammation
• Natriuretic peptides (BNP or NT-proBNP): Elevated in heart failure; helpful when dyspnea etiology unclear

Cardiac imaging

• Chest X-ray: Assess for pneumonia, pulmonary edema (Kerley B lines, alveolar infiltrates), cardiomegaly, pleural effusion
• Transthoracic echocardiography: Indicated if structural heart disease suspected or to assess ejection fraction and wall motion abnormalities in setting of ACS; evaluate for valvular disease, pericardial effusion, or myocarditis

Specialized testing

• D-dimer or CT pulmonary angiography (CTPA): If pulmonary embolism suspected based on clinical presentation and risk factors; D-dimer useful for risk stratification in low-probability cases
• Stress testing or coronary angiography: Reserved for evaluation of underlying coronary disease when ACS suspected or cannot be excluded
• Holter monitor or event monitor: If palpitations episodic and diagnosis unclear; typically shows normal sinus rhythm with rate variation

Diagnostic approach algorithm

1. 1.Confirm sinus tachycardia on ECG with appropriate P-wave morphology
2. 2.Assess acuity: acute presentation suggests ACS, PE, infection, or decompensated heart failure; chronic tachycardia suggests hyperthyroidism, anxiety, or chronic compensation
3. 3.Target examination and investigations toward most likely etiology based on clinical context
4. 4.Always obtain troponin and ECG in acute presentations
5. 5.Fever mandates infectious workup; hypoxemia requires pulmonary investigation
6. 6.If no obvious cause identified after initial assessment, obtain TSH and consider echocardiography

General principles

Treatment by underlying cause

Acute coronary syndrome

• Urgent revascularization (PCI or fibrinolysis) for STEMI
• Dual antiplatelet therapy, anticoagulation, beta-blockers for symptom and ischemia relief
• Aspirin 325 mg, P2Y₁₂ inhibitor (clopidogrel, ticagrelor, prasugrel), unfractionated heparin or LMWH
• Beta-blockers (metoprolol IV 5 mg q5min × 3, then oral; or esmolol IV 500 mcg/kg load then 50-200 mcg/kg/min): Reduce myocardial oxygen demand and provide angina relief; contraindicated if bradycardic, hypotensive, or with severe decompensated heart failure

Heart failure

• ACE inhibitors/ARBs and beta-blockers: Cornerstone therapy addressing underlying systolic dysfunction
• Diuretics: IV furosemide for acute decompensation with pulmonary edema
• Inotropic support (dobutamine, milrinone) if cardiogenic shock; addresses tachycardia by improving cardiac output and reducing compensatory mechanisms
• Afterload reduction with nitroprusside or nitroglycerin if hypertensive

Fever/infection

• Acetaminophen or NSAIDs: Antipyretics reduce fever and associated tachycardia; 10-15 bpm reduction per 1°C fever reduction expected
• Antibiotics: Broad-spectrum coverage pending culture results in sepsis (e.g., piperacillin-tazobactam or ceftriaxone + vancomycin depending on clinical context)
• Fluid resuscitation: Crystalloid bolus for sepsis-associated hypotension
• Vasopressors (norepinephrine preferred) if hypotensive despite fluids

Pulmonary embolism

• Anticoagulation: Unfractionated heparin IV or LMWH SC; fondaparinux; or DOACs depending on hemodynamic stability and renal function
• Thrombolysis (tissue plasminogen activator, alteplase): For massive PE with hemodynamic instability; rapid heart rate typically resolves with restoration of pulmonary perfusion
• Oxygen to target SpO₂ >90%
• Mechanical thrombectomy or IVC filter in select cases

Hyperthyroidism/thyrotoxicosis

• Beta-blockers (propranolol preferred as also inhibits peripheral T4 to T3 conversion): Control tachycardia and adrenergic symptoms while awaiting definitive therapy
• Antithyroid drugs: Propylthiouracil (PTU) or methimazole for Graves' disease
• Iodine preparations (Lugol's solution or saturated solution of potassium iodide [SSKI]): After antithyroid drugs initiated; inhibits thyroid hormone release
• Beta-blockers: Propranolol 20-40 mg PO TID or esmolol IV for acute thyroid storm

Anemia

• Blood transfusion: RBC transfusion for symptomatic anemia (hemoglobin typically <7 g/dL; higher threshold if coronary disease or cardiopulmonary disease present)
• Iron replacement: Oral ferrous sulfate 325 mg daily or IV iron for iron-deficiency anemia
• Erythropoiesis-stimulating agents: For anemia of chronic kidney disease or malignancy-related anemia
• Treating underlying cause: GI bleeding cessation, B12/folate replacement for nutritional deficiencies

Hypovolemia/dehydration

• IV fluid resuscitation: Normal saline bolus (500-1000 mL); reassess perfusion and adjust based on response
• Ongoing fluid maintenance: Address ongoing losses
• Tachycardia should improve as perfusion restored and baroreceptor reflex deactivates

Anxiety/panic disorder

• Reassurance and education: Explanation of benign nature of palpitations; psychological reassurance reduces symptoms
• Cognitive behavioral therapy: First-line psychological intervention
• Beta-blockers (propranolol 20 mg BID-TID): Symptomatic relief of physical manifestations
• Benzodiazepines: Short-term use (e.g., lorazepam 0.5-1 mg BID); avoid chronic use due to dependence risk
• SSRIs:

Complications of the tachycardia itself

• Demand ischemia (type 2 MI): Diastolic filling time — and therefore coronary perfusion, which occurs in diastole — shortens disproportionately as rate rises, while wall stress and oxygen demand climb. Signals: anginal chest pain, ST depression, rising high-sensitivity troponin without occlusive thrombus. Emergency when accompanied by ischemic ECG changes.
• Hemodynamic decompensation: Loss of atrial kick timing and inadequate ventricular filling reduce stroke volume in stiff or stenotic ventricles (aortic stenosis, hypertrophic cardiomyopathy, tamponade). Signals: hypotension, cool extremities, rising lactate.
• Tachycardia-mediated cardiomyopathy: Persistent, chronically elevated rates (most often inappropriate sinus tachycardia or an unrecognized incessant atrial tachycardia) cause myocyte energy depletion and remodeling. Signals: new LV dilation with reduced EF on echocardiography that improves once rate is controlled — a diagnosis recognized in the 2015 ACC/AHA/HRS supraventricular tachycardia guideline.
• Masked shock: Tachycardia is often the only early sign of class II hemorrhage or evolving sepsis; blood pressure falls late, especially in young patients. Persistent tachycardia after apparently adequate resuscitation should trigger a search for ongoing bleeding or an undrained source, consistent with Surviving Sepsis Campaign emphasis on serial perfusion reassessment. Emergency.

Complications of treatment

• Beta blockers or non-dihydropyridine calcium channel blockers given to a compensating patient: Removing the chronotropic response in hypovolemia, sepsis, or cardiogenic shock collapses cardiac output. Signal: abrupt hypotension after rate slows. Emergency.
• Beta blockade in cocaine or amphetamine toxicity: Unopposed alpha stimulation may worsen hypertension and coronary vasoconstriction; the AHA advises benzodiazepines first for cocaine-associated chest pain.
• Ivabradine (used for inappropriate sinus tachycardia): funny-current inhibition causes bradycardia, atrial fibrillation, and luminous phosphenes; it is fetotoxic and contraindicated in pregnancy.
• Adenosine given for a misread rhythm: transient sinus arrest, flushing, and bronchospasm in asthmatics, with no diagnostic benefit if the rhythm is sinus.

• Rate ceiling rule: Adult resting sinus tachycardia rarely exceeds roughly 220 minus age; a fixed rate near 150 bpm should raise suspicion for atrial flutter with 2:1 block, and a regular narrow-complex rate above ~170 bpm suggests AVNRT/AVRT rather than sinus tachycardia.
• Onset behavior is the discriminator: sinus tachycardia warms up and cools down gradually; paroxysmal SVT starts and stops abruptly. Vagal maneuvers or adenosine transiently slow sinus tachycardia and unmask buried P waves but do not terminate it — a diagnostic, not therapeutic, maneuver in this setting.
• Single best next step is almost always to find the cause, not to slow the rate. Treating compensatory tachycardia with a beta blocker in hypovolemia or sepsis is the classic wrong answer; so is cardioverting sinus tachycardia.
• The association examiners love: fever raises heart rate roughly 10 bpm per 1°C. Relative bradycardia (pulse–temperature dissociation, Faget sign) points away from routine infection toward Legionella, typhoid fever, or intracellular pathogens.
• Postoperative or post-immobilization tachycardia with hypoxia and clear lungs = pulmonary embolism until excluded; unexplained persistent tachycardia in a trauma or GI-bleed patient means ongoing hemorrhage before hypotension appears.
• Inappropriate sinus tachycardia versus POTS: both are diagnoses of exclusion, but POTS requires a sustained heart rate rise on standing within 10 minutes without orthostatic hypotension. The 2015 ACC/AHA/HRS SVT guideline lists ivabradine as an option for symptomatic inappropriate sinus tachycardia after reversible causes are excluded.
• Common distractor: an upright P wave in lead II before every QRS is what makes it sinus. If P waves are inverted in II/III/aVF or absent, rethink the diagnosis — that is atrial or junctional tachycardia, not sinus.
• Pregnancy and thyrotoxicosis are the two chronic causes most often missed; check TSH when tachycardia is unexplained.